SIMILAR PATTERNS OF AMINO ACIDS FOR 3MIY_A_B49A1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 31 LYS A 33 VAL A 64 PHE A 80 LEU A 133 ASP A 144	None	0.74A	3miyA-1h4lA: 20.5	3miyA-1h4lA: 24.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 10 ALA A 31 LYS A 33 VAL A 64 PHE A 80 PHE A 82 LEU A 133	None	0.66A	3miyA-1h4lA: 20.5	3miyA-1h4lA: 24.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 428 LYS A 430 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.76A	3miyA-1k2pA: 26.8	3miyA-1k2pA: 57.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 428 VAL A 458 MET A 477 GLY A 480 LEU A 528 SER A 538 ASP A 539	None	0.83A	3miyA-1k2pA: 26.8	3miyA-1k2pA: 57.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 220 LYS A 222 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.81A	3miyA-1k9aA: 32.6	3miyA-1k9aA: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 220 LYS A 222 VAL A 249 MET A 269 GLY A 272 LEU A 321	None	0.70A	3miyA-1k9aA: 32.6	3miyA-1k9aA: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 220 VAL A 249 MET A 269 GLY A 272 LEU A 321 SER A 331	None	0.77A	3miyA-1k9aA: 32.6	3miyA-1k9aA: 26.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	ALA A 606 VAL A 638 PHE A 654 MET A 657 GLY A 660 LEU A 731	None	0.72A	3miyA-1lufA: 32.5	3miyA-1lufA: 32.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 288 VAL A 318 PHE A 336 MET A 337 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 ( 4.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	3miyA-1opkA: 30.8	3miyA-1opkA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 99 VAL A 131 MET A 150 GLY A 153 LEU A 201 ASP A 212	ATP A 535 (-3.6A) 5EA A1001 (-4.5A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.72A	3miyA-1s9iA: 10.2	3miyA-1s9iA: 26.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 389 VAL A 419 PHE A 435 MET A 438 GLY A 441 LEU A 489 SER A 499 ASP A 500	None	0.80A	3miyA-1snxA: 27.7	3miyA-1snxA: 98.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ILE A 369 ALA A 389 LYS A 391 PHE A 437 MET A 438 GLY A 441 LEU A 489	None	0.85A	3miyA-1snxA: 27.7	3miyA-1snxA: 98.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	ILE A 369 ALA A 389 VAL A 419 PHE A 435 PHE A 437 MET A 438 GLY A 441 LEU A 489 SER A 499	None	0.73A	3miyA-1snxA: 27.7	3miyA-1snxA: 98.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ua2	CELL DIVISION PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 39 LYS A 41 PHE A 91 PHE A 93 MET A 94 LEU A 144	ATP A 381 (-3.6A) ATP A 381 (-2.9A) None ATP A 381 (-4.1A) None None	0.63A	3miyA-1ua2A: 23.3	3miyA-1ua2A: 25.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	6	ILE A 10 ALA A 30 VAL A 63 PHE A 79 LEU A 132 ASP A 143	None	0.61A	3miyA-1v0bA: 23.3	3miyA-1v0bA: 25.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 293 VAL A 323 PHE A 340 MET A 341 GLY A 344 LEU A 393 ASP A 404	QUE A 1 (-3.5A) None QUE A 1 (-4.2A) None QUE A 1 (-3.0A) QUE A 1 (-4.4A) None	0.55A	3miyA-2hckA: 31.4	3miyA-2hckA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	8	ILE A 635 ALA A 659 LYS A 661 PHE A 709 MET A 710 GLY A 713 LEU A 761 SER A 771	ADP A 400 (-4.9A) ADP A 400 (-3.2A) ADP A 400 (-2.7A) None None ADP A 400 ( 4.2A) ADP A 400 ( 4.7A) ADP A 400 ( 4.8A)	0.68A	3miyA-2henA: 31.1	3miyA-2henA: 37.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 271 LYS A 273 VAL A 301 PHE A 318 MET A 319 GLY A 322 LEU A 371	1BM A 499 (-3.6A) 1BM A 499 (-3.8A) None 1BM A 499 (-4.1A) None 1BM A 499 (-3.5A) 1BM A 499 (-4.4A)	0.58A	3miyA-2hk5A: 26.0	3miyA-2hk5A: 39.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 269 LYS A 271 VAL A 299 PHE A 317 MET A 318 GLY A 321 LEU A 370	GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-4.6A) GIN A 600 (-4.3A) None None GIN A 600 (-4.7A)	0.57A	3miyA-2hz0A: 31.8	3miyA-2hz0A: 42.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 10 ALA A 31 LYS A 33 VAL A 64 PHE A 80 PHE A 82 LEU A 134	None	0.78A	3miyA-2jgzA: 19.6	3miyA-2jgzA: 29.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ILE A 428 ALA A 452 LYS A 454 VAL A 484 GLY A 505 LEU A 553	BII A1687 (-3.8A) BII A1687 (-3.5A) BII A1687 (-2.9A) None BII A1687 (-3.6A) BII A1687 (-4.2A)	0.79A	3miyA-2jkmA: 33.1	3miyA-2jkmA: 37.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 271 LYS A 273 VAL A 301 MET A 319 GLY A 322 LEU A 371	1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) None 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.75A	3miyA-2og8A: 32.2	3miyA-2og8A: 42.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	ALA A 367 LYS A 369 VAL A 399 GLY A 418 LEU A 468 SER A 478 ASP A 479	ANP A 615 (-3.3A) ANP A 615 (-3.1A) None ANP A 615 ( 4.0A) ANP A 615 (-4.7A) MG A 614 ( 4.1A) MG A 614 ( 3.2A)	1.23A	3miyA-2ozoA: 29.4	3miyA-2ozoA: 19.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2pmi	CYCLIN-DEPENDENT PROTEIN KINASE PHO85 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	7	ALA A 34 LYS A 36 VAL A 66 PHE A 82 PHE A 84 MET A 85 LEU A 140	AGS A3001 (-3.5A) AGS A3001 (-3.4A) None None AGS A3001 ( 4.5A) None None	0.65A	3miyA-2pmiA: 21.8	3miyA-2pmiA: 29.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	7	ILE B 47 ALA B 67 LYS B 69 VAL B 98 MET B 117 GLY B 120 LEU B 171	None	0.58A	3miyA-2qkwB: 24.8	3miyA-2qkwB: 30.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	ILE B 47 LYS B 69 VAL B 98 MET B 117 LEU B 171 ASP B 182	None	0.82A	3miyA-2qkwB: 24.8	3miyA-2qkwB: 30.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 651 LYS A 653 MET A 702 GLY A 705 LEU A 753 SER A 763	PTR A 701 ( 4.7A) None PTR A 701 ( 3.5A) None None None	0.52A	3miyA-2qobA: 27.5	3miyA-2qobA: 38.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ILE A 681 ALA A 705 LYS A 707 MET A 756 GLY A 759 LEU A 807 SER A 817	None	0.63A	3miyA-2r2pA: 29.6	3miyA-2r2pA: 36.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 749 LYS A 751 MET A 799 GLY A 802 LEU A 850 ASP A 861	GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-4.1A)	0.78A	3miyA-2r4bA: 27.0	3miyA-2r4bA: 33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 749 VAL A 781 MET A 799 GLY A 802 LEU A 850 ASP A 861	GW7 A 1 (-3.3A) GW7 A 1 ( 4.7A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-4.1A)	0.69A	3miyA-2r4bA: 27.0	3miyA-2r4bA: 33.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	STE20-RELATED KINASE ADAPTER PROTEIN ALPHA (Homo sapiens)	PF00069 (Pkinase)	7	ILE B 75 VAL B 131 PHE B 149 MET B 150 GLY B 153 LEU B 202 SER B 212	ANP B 432 (-4.4A) None ANP B 432 ( 4.9A) None ANP B 432 ( 4.2A) ANP B 432 ( 4.7A) None	0.89A	3miyA-2wtkB: 24.4	3miyA-2wtkB: 25.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	ILE A 627 ALA A 651 MET A 702 GLY A 705 LEU A 753 SER A 763	None Q9G A1898 (-3.2A) None Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A) Q9G A1898 (-3.2A)	0.33A	3miyA-2xyuA: 31.1	3miyA-2xyuA: 39.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 30 ALA A 51 MET A 110 GLY A 113 LEU A 160 SER A 170 ASP A 171	B49 A1294 (-3.9A) B49 A1294 (-3.2A) None B49 A1294 (-3.6A) B49 A1294 (-4.4A) B49 A1294 ( 4.9A) B49 A1294 (-4.2A)	0.90A	3miyA-2y7jA: 24.0	3miyA-2y7jA: 22.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 30 ALA A 51 PHE A 107 MET A 110 GLY A 113 LEU A 160	B49 A1294 (-3.9A) B49 A1294 (-3.2A) B49 A1294 (-4.0A) None B49 A1294 (-3.6A) B49 A1294 (-4.4A)	0.73A	3miyA-2y7jA: 24.0	3miyA-2y7jA: 22.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	ALA A 273 LYS A 275 VAL A 303 PHE A 321 MET A 322 GLY A 325 LEU A 374	None	0.57A	3miyA-2zv7A: 32.9	3miyA-2zv7A: 41.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c0i	PERIPHERAL PLASMA MEMBRANE PROTEIN CASK (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 18 ALA A 39 LYS A 41 PHE A 91 PHE A 93 MET A 94	3AM A 338 (-4.5A) 3AM A 338 (-3.3A) 3AM A 338 (-2.9A) 3AM A 338 (-3.6A) 3AM A 338 ( 4.6A) None	0.81A	3miyA-3c0iA: 24.3	3miyA-3c0iA: 26.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 220 LYS A 222 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.81A	3miyA-3d7uA: 27.4	3miyA-3d7uA: 43.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 220 LYS A 222 VAL A 249 MET A 269 GLY A 272 LEU A 321	None	0.70A	3miyA-3d7uA: 27.4	3miyA-3d7uA: 43.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 220 VAL A 249 MET A 269 GLY A 272 LEU A 321 SER A 331	None	0.77A	3miyA-3d7uA: 27.4	3miyA-3d7uA: 43.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	8	ILE A 639 ALA A 663 VAL A 695 PHE A 713 MET A 714 GLY A 717 LEU A 765 SER A 775	IHZ A1001 ( 4.8A) IHZ A1001 (-3.3A) IHZ A1001 ( 4.9A) None None IHZ A1001 ( 3.9A) IHZ A1001 (-4.6A) IHZ A1001 (-3.7A)	0.80A	3miyA-3dkoA: 33.0	3miyA-3dkoA: 37.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ALA A 665 MET A 716 GLY A 719 LEU A 767 SER A 777 ASP A 778	None None GOL A 403 (-3.4A) None None None	0.77A	3miyA-3kulA: 33.9	3miyA-3kulA: 37.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 25 ALA A 46 LYS A 48 VAL A 79 PHE A 103 PHE A 105 LEU A 156	None	0.87A	3miyA-3mi9A: 23.3	3miyA-3mi9A: 26.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	7	ALA A 49 LYS A 51 VAL A 82 PHE A 98 PHE A 100 MET A 101 LEU A 151	ADP A 314 (-3.5A) ADP A 314 (-2.8A) None None ADP A 314 ( 4.3A) None ADP A 314 (-4.6A)	0.55A	3miyA-3nizA: 24.8	3miyA-3nizA: 25.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 570 VAL A 601 PHE A 617 MET A 620 GLY A 623 LEU A 686	0F4 A 902 (-3.2A) None 0F4 A 902 (-3.4A) None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.59A	3miyA-3v5qA: 31.9	3miyA-3v5qA: 36.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 96 LYS A 98 VAL A 128 MET A 147 GLY A 150 LEU A 198 ASP A 209	ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.75A	3miyA-3wigA: 24.2	3miyA-3wigA: 26.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 866 VAL A 899 PHE A 918 GLY A 922 LEU A1035 ASP A1046	LEV A1201 (-3.5A) None LEV A1201 (-4.7A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.4A)	0.65A	3miyA-3wzdA: 31.4	3miyA-3wzdA: 33.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zdu	CYCLIN-DEPENDENT KINASE-LIKE 3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 31 LYS A 33 VAL A 63 PHE A 79 PHE A 81 LEU A 132	38R A 350 (-3.4A) 38R A 350 (-2.9A) 38R A 350 ( 4.9A) 38R A 350 (-4.1A) 38R A 350 (-4.2A) 38R A 350 (-4.3A)	0.64A	3miyA-3zduA: 24.2	3miyA-3zduA: 25.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	ILE A 625 ALA A 649 LYS A 651 PHE A 699 MET A 700 GLY A 703 LEU A 751 SER A 761 ASP A 762	None	0.59A	3miyA-3zfxA: 34.8	3miyA-3zfxA: 38.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 866 LYS A 868 VAL A 899 PHE A 918 GLY A 922 LEU A1035	B49 A2000 (-3.5A) B49 A2000 (-3.0A) B49 A2000 ( 4.6A) B49 A2000 (-4.4A) B49 A2000 ( 3.7A) B49 A2000 (-4.5A)	0.79A	3miyA-4agdA: 30.2	3miyA-4agdA: 30.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 586 VAL A 617 PHE A 633 MET A 636 GLY A 639 LEU A 699	LTI A1839 (-3.3A) None LTI A1839 (-3.5A) None LTI A1839 (-3.4A) LTI A1839 (-4.2A)	0.61A	3miyA-4at3A: 31.6	3miyA-4at3A: 38.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ILE A 97 ALA A 121 LYS A 123 PHE A 171 MET A 172 GLY A 175 LEU A 223	30K A1365 (-4.5A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-4.4A) None 30K A1365 (-3.5A) 30K A1365 (-4.5A)	0.58A	3miyA-4aw5A: 30.6	3miyA-4aw5A: 39.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ILE A 97 ALA A 121 PHE A 171 MET A 172 GLY A 175 LEU A 223 SER A 233 ASP A 234	30K A1365 (-4.5A) 30K A1365 (-3.2A) 30K A1365 (-4.4A) None 30K A1365 (-3.5A) 30K A1365 (-4.5A) 30K A1365 ( 3.7A) 30K A1365 (-3.3A)	0.83A	3miyA-4aw5A: 30.6	3miyA-4aw5A: 39.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 63 VAL A 94 PHE A 112 GLY A 116 LEU A 164 ASP A 175	XZN A1317 (-3.5A) XZN A1317 (-4.4A) XZN A1317 (-4.5A) XZN A1317 ( 3.7A) XZN A1317 (-4.7A) XZN A1317 (-3.2A)	0.59A	3miyA-4bc6A: 22.2	3miyA-4bc6A: 28.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	ILE A 567 ALA A 588 LYS A 590 GLY A 642 LEU A 690 SER A 700 ASP A 701	GUI A 901 (-4.0A) GUI A 901 (-3.4A) GUI A 901 (-2.8A) GUI A 901 (-3.5A) GUI A 901 (-4.3A) GUI A 901 (-3.1A) GUI A 901 ( 4.1A)	0.75A	3miyA-4e93A: 35.0	3miyA-4e93A: 34.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	ILE A 567 ALA A 588 LYS A 590 VAL A 620 GLY A 642 LEU A 690 SER A 700	GUI A 901 (-4.0A) GUI A 901 (-3.4A) GUI A 901 (-2.8A) None GUI A 901 (-3.5A) GUI A 901 (-4.3A) GUI A 901 (-3.1A)	0.64A	3miyA-4e93A: 35.0	3miyA-4e93A: 34.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 541 VAL A 572 PHE A 588 MET A 591 GLY A 594 LEU A 656	None	0.50A	3miyA-4f0iA: 25.2	3miyA-4f0iA: 38.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 400 LYS A 402 GLY A 454 LEU A 501 SER A 511 ASP A 512	0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) 0SB A 701 (-3.5A) 0SB A 701 (-4.4A) 0SB A 701 (-3.2A) 0SB A 701 (-3.9A)	0.81A	3miyA-4f4pA: 32.1	3miyA-4f4pA: 38.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501 SER A 511	0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A) 0SB A 701 (-3.2A)	0.78A	3miyA-4f4pA: 32.1	3miyA-4f4pA: 38.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fie	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF00786 (PBD)	7	ILE A 327 ALA A 348 LYS A 350 VAL A 379 PHE A 397 LEU A 447 SER A 457	None ANP A1001 (-3.6A) ANP A1001 (-3.0A) None ANP A1001 ( 4.6A) ANP A1001 (-4.7A) ANP A1001 ( 4.4A)	0.80A	3miyA-4fieA: 23.1	3miyA-4fieA: 24.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fie	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF00786 (PBD)	7	ILE A 327 LYS A 350 VAL A 379 PHE A 397 GLY A 401 LEU A 447 SER A 457	None ANP A1001 (-3.0A) None ANP A1001 ( 4.6A) None ANP A1001 (-4.7A) ANP A1001 ( 4.4A)	0.79A	3miyA-4fieA: 23.1	3miyA-4fieA: 24.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501 SER A 511 ASP A 512	ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 (-4.8A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A) MG A 702 ( 4.2A) MG A 702 ( 3.1A)	1.00A	3miyA-4fl3A: 31.3	3miyA-4fl3A: 19.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A1148 LYS A1150 VAL A1180 MET A1199 GLY A1202 LEU A1256	0UV A1501 (-3.4A) 0UV A1501 (-3.7A) 0UV A1501 ( 4.9A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A)	0.61A	3miyA-4fodA: 31.5	3miyA-4fodA: 36.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 293 LYS A 295 VAL A 323 MET A 341 GLY A 344 LEU A 393 ASP A 404	0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A) 0J9 A 601 (-3.1A)	0.71A	3miyA-4k11A: 31.6	3miyA-4k11A: 28.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	8	ILE A 413 ALA A 434 LYS A 436 VAL A 465 PHE A 483 GLY A 487 LEU A 533 SER A 543	B49 A 701 (-4.2A) B49 A 701 (-3.2A) None None B49 A 701 (-4.3A) B49 A 701 ( 3.7A) B49 A 701 (-4.5A) B49 A 701 (-3.0A)	0.65A	3miyA-4ks8A: 24.9	3miyA-4ks8A: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	8	ILE A 413 ALA A 434 VAL A 465 PHE A 483 GLY A 487 LEU A 533 SER A 543 ASP A 544	B49 A 701 (-4.2A) B49 A 701 (-3.2A) None B49 A 701 (-4.3A) B49 A 701 ( 3.7A) B49 A 701 (-4.5A) B49 A 701 (-3.0A) B49 A 701 (-4.6A)	0.73A	3miyA-4ks8A: 24.9	3miyA-4ks8A: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l01	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LYS A 622 VAL A 651 PHE A 669 GLY A 673 LEU A 721 SER A 738	None	0.75A	3miyA-4l01A: 28.9	3miyA-4l01A: 28.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	ALA A 293 LYS A 295 VAL A 323 MET A 341 GLY A 344 LEU A 393 ASP A 404	VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.8A) None VGG A 601 ( 3.2A) VGG A 601 (-4.5A) VGG A 601 ( 4.7A)	0.75A	3miyA-4lggA: 31.9	3miyA-4lggA: 40.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	7	ALA A 218 LYS A 220 VAL A 255 MET A 274 LEU A 324 SER A 334 ASP A 335	29X A 702 (-3.1A) 29X A 702 (-3.6A) 29X A 702 (-4.8A) None 29X A 702 (-4.6A) 29X A 702 (-3.4A) 29X A 702 (-4.4A)	0.93A	3miyA-4mk0A: 15.9	3miyA-4mk0A: 17.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	7	LYS A 220 VAL A 255 MET A 274 GLY A 277 LEU A 324 SER A 334 ASP A 335	29X A 702 (-3.6A) 29X A 702 (-4.8A) None None 29X A 702 (-4.6A) 29X A 702 (-3.4A) 29X A 702 (-4.4A)	0.89A	3miyA-4mk0A: 15.9	3miyA-4mk0A: 17.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ILE A 619 ALA A 644 MET A 695 GLY A 698 LEU A 746 SER A 756	None	0.69A	3miyA-4p2kA: 34.0	3miyA-4p2kA: 38.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	ALA A 35 LYS A 37 VAL A 65 MET A 84 GLY A 87 LEU A 136	ACP A1264 (-2.9A) None None None ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.61A	3miyA-4ueuA: 33.1	3miyA-4ueuA: 48.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xbr	PROTEIN FAM212A,SERINE/THREO NINE-PROTEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF15342 (FAM212)	8	ILE A 327 ALA A 348 LYS A 350 VAL A 379 PHE A 397 LEU A 447 SER A 457 ASP A 458	None ATP A 601 ( 3.7A) ATP A 601 (-2.8A) None ATP A 601 (-4.6A) None ATP A 601 ( 4.6A) ATP A 601 ( 2.5A)	0.84A	3miyA-4xbrA: 19.4	3miyA-4xbrA: 24.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xbr	PROTEIN FAM212A,SERINE/THREO NINE-PROTEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF15342 (FAM212)	7	LYS A 350 VAL A 379 PHE A 397 GLY A 401 LEU A 447 SER A 457 ASP A 458	ATP A 601 (-2.8A) None ATP A 601 (-4.6A) None None ATP A 601 ( 4.6A) ATP A 601 ( 2.5A)	0.85A	3miyA-4xbrA: 19.4	3miyA-4xbrA: 24.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	7	ALA B 288 LYS B 290 VAL B 318 PHE B 336 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.79A	3miyA-4xeyB: 26.2	3miyA-4xeyB: 30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 428 VAL A 458 MET A 477 GLY A 480 LEU A 528 SER A 538 ASP A 539	None	0.67A	3miyA-4xi2A: 29.4	3miyA-4xi2A: 42.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	8	ALA A 428 LYS A 430 VAL A 458 MET A 477 GLY A 480 LEU A 528 SER A 538 ASP A 539	746 A 702 (-2.4A) 746 A 702 (-3.7A) None None 746 A 702 (-3.6A) 746 A 702 (-4.4A) 746 A 702 ( 3.8A) 746 A 702 (-3.7A)	0.65A	3miyA-4y93A: 33.1	3miyA-4y93A: 35.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 10 ALA A 31 LYS A 33 VAL A 64 PHE A 80 LEU A 135 ASP A 146	None	0.74A	3miyA-4yc6A: 23.5	3miyA-4yc6A: 30.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 10 ALA A 31 VAL A 64 PHE A 80 PHE A 82 LEU A 135 ASP A 146	None	0.66A	3miyA-4yc6A: 23.5	3miyA-4yc6A: 30.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	ALA A 214 LYS A 216 VAL A 248 MET A 267 LEU A 319 SER A 329	AN2 A 601 (-3.6A) AN2 A 601 ( 3.9A) None None None AN2 A 601 ( 4.5A)	0.80A	3miyA-4yhjA: 20.3	3miyA-4yhjA: 18.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci6	MITOGEN-ACTIVATED PROTEIN KINASE 6 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	ILE A 69 ALA A 90 LYS A 92 VAL A 123 MET A 147 LEU A 196	None	0.54A	3miyA-5ci6A: 22.0	3miyA-5ci6A: 23.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 396 ALA A 417 LYS A 419 VAL A 449 GLY A 471 LEU A 518	GUI A 701 (-4.1A) GUI A 701 ( 3.9A) GUI A 701 (-3.1A) None GUI A 701 (-3.6A) GUI A 701 (-4.4A)	0.80A	3miyA-5jznA: 23.3	3miyA-5jznA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 639 ALA A 663 PHE A 713 MET A 714 LEU A 765 SER A 775	6P6 A1001 (-4.0A) 6P6 A1001 (-3.3A) 6P6 A1001 ( 4.5A) None 6P6 A1001 (-4.5A) 6P6 A1001 ( 3.7A)	0.45A	3miyA-5l6oA: 32.6	3miyA-5l6oA: 38.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	9	ILE A 889 ALA A 909 LYS A 911 VAL A 940 PHE A 958 MET A 959 GLY A 962 LEU A1016 ASP A1027	None ATP A1200 (-3.5A) ATP A1200 (-3.8A) None ATP A1200 ( 4.0A) None ATP A1200 ( 4.0A) ATP A1200 (-4.6A) ATP A1200 (-4.1A)	0.65A	3miyA-5lpyA: 24.6	3miyA-5lpyA: 30.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	9	ILE A 889 ALA A 909 LYS A 911 VAL A 940 PHE A 958 MET A 959 GLY A 962 LEU A1016 SER A1026	None ATP A1200 (-3.5A) ATP A1200 (-3.8A) None ATP A1200 ( 4.0A) None ATP A1200 ( 4.0A) ATP A1200 (-4.6A) ATP A1200 ( 4.7A)	0.49A	3miyA-5lpyA: 24.6	3miyA-5lpyA: 30.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	9	ILE A 889 ALA A 909 LYS A 911 VAL A 940 PHE A 958 MET A 959 GLY A 962 LEU A1016 ASP A1027	ADP A1200 (-4.7A) ADP A1200 (-3.5A) ADP A1200 ( 4.3A) None ADP A1200 (-4.1A) None ADP A1200 ( 4.0A) ADP A1200 (-4.7A) ADP A1200 (-3.4A)	0.66A	3miyA-5lpzA: 24.5	3miyA-5lpzA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	8	ILE A 889 ALA A 909 VAL A 940 PHE A 958 MET A 959 GLY A 962 LEU A1016 SER A1026	ADP A1200 (-4.7A) ADP A1200 (-3.5A) None ADP A1200 (-4.1A) None ADP A1200 ( 4.0A) ADP A1200 (-4.7A) ADP A1200 ( 4.6A)	0.64A	3miyA-5lpzA: 24.5	3miyA-5lpzA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tos	SERINE/THREONINE-PRO TEIN KINASE BIK1 (Arabidopsis thaliana)	no annotation	7	ALA A 103 VAL A 134 PHE A 152 MET A 153 GLY A 156 LEU A 209 SER A 219	None	0.98A	3miyA-5tosA: 22.9	3miyA-5tosA: 14.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.81A	3miyA-5u6bA: 32.2	3miyA-5u6bA: 36.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 98 ALA A 119 LYS A 121 VAL A 153 MET A 172 LEU A 221	None	0.78A	3miyA-5u7qA: 19.6	3miyA-5u7qA: 23.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ALA A 218 LYS A 220 VAL A 255 MET A 274 LEU A 324 SER A 334 ASP A 335	QRW A 601 (-3.4A) QRW A 601 (-3.0A) None MES A 604 (-3.9A) None QRW A 601 ( 3.7A) QRW A 601 (-3.7A)	0.95A	3miyA-5uuuA: 22.1	3miyA-5uuuA: 18.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LYS A 220 VAL A 255 MET A 274 GLY A 277 LEU A 324 SER A 334 ASP A 335	QRW A 601 (-3.0A) None MES A 604 (-3.9A) None None QRW A 601 ( 3.7A) QRW A 601 (-3.7A)	0.96A	3miyA-5uuuA: 22.1	3miyA-5uuuA: 18.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	no annotation	9	ILE A 327 ALA A 348 LYS A 350 VAL A 379 PHE A 397 GLY A 401 LEU A 447 SER A 457 ASP A 458	M77 A 601 ( 4.8A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 (-3.2A) M77 A 601 ( 3.5A)	0.87A	3miyA-5vefA: 24.1	3miyA-5vefA: 27.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5win	- (-)	no annotation	6	LYS A 581 VAL A 610 PHE A 628 GLY A 632 LEU A 680 SER A 698	SKE A 901 ( 4.7A) SKE A 901 ( 4.7A) SKE A 901 (-3.6A) SKE A 901 (-3.1A) SKE A 901 (-4.1A) SKE A 901 (-3.3A)	0.70A	3miyA-5winA: 29.2	3miyA-5winA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	7	ILE A 733 ALA A 754 LYS A 756 VAL A 787 PHE A 813 MET A 816 LEU A 866	CJM A1102 (-3.4A) CJM A1102 (-3.1A) None None CJM A1102 ( 4.4A) None CJM A1102 (-4.4A)	0.82A	3miyA-6b3eA: 23.9	3miyA-6b3eA: 16.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	no annotation	8	ILE A 218 ALA A 237 LYS A 239 VAL A 272 PHE A 290 GLY A 294 LEU A 347 ASP A 358	DL1 A 601 (-4.0A) DL1 A 601 (-3.4A) DL1 A 601 ( 4.1A) DL1 A 601 ( 4.8A) DL1 A 601 (-4.3A) DL1 A 601 (-3.5A) DL1 A 601 (-3.9A) DL1 A 601 (-3.1A)	0.61A	3miyA-6bfnA: 25.0	3miyA-6bfnA: 15.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	7	ILE A 171 ALA A 192 LYS A 194 VAL A 249 PHE A 267 GLY A 273 LEU A 319	BI9 A 501 (-4.0A) BI9 A 501 (-3.3A) NH4 A 506 ( 4.4A) None BI9 A 501 ( 4.2A) BI9 A 501 (-3.3A) BI9 A 501 (-4.7A)	0.59A	3miyA-6bqlA: 23.0	3miyA-6bqlA: 14.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	6	ALA A 906 LYS A 908 VAL A 938 PHE A 958 GLY A 962 LEU A1010	ADP A1201 (-3.4A) ADP A1201 (-2.8A) None None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.62A	3miyA-6c7yA: 29.7	3miyA-6c7yA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	7	ILE A 134 ALA A 155 LYS A 157 VAL A 212 PHE A 230 GLY A 236 LEU A 282	H1N A 501 (-4.3A) H1N A 501 (-3.4A) H1N A 501 (-2.8A) H1N A 501 (-4.9A) H1N A 501 (-3.7A) H1N A 501 (-3.6A) H1N A 501 (-4.8A)	0.58A	3miyA-6ccfA: 23.4	3miyA-6ccfA: 13.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	ILE A 171 ALA A 192 VAL A 249 PHE A 267 GLY A 273 LEU A 319	F6J A 501 (-4.3A) F6J A 501 (-3.4A) None F6J A 501 (-3.7A) F6J A 501 ( 3.7A) F6J A 501 (-4.5A)	0.77A	3miyA-6cmjA: 22.9	3miyA-6cmjA: 16.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	6	ALA A 211 VAL A 246 MET A 265 GLY A 268 LEU A 318 SER A 328	CJT A 502 (-3.4A) None CJT A 502 (-4.9A) CJT A 502 ( 4.3A) CJT A 502 (-4.7A) CJT A 502 ( 4.3A)	0.73A	3miyA-6f3dA: 25.4	3miyA-6f3dA: 13.17

[["3MIY_A_B49A1_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ALA A  31;LYS A  33;VAL A  64;PHE A  80;LEU A 133;ASP A 144","None","0.74A","3miyA-1h4lA:20.5","3miyA-1h4lA:24.35"],["3MIY_A_B49A1_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",7,"ILE A  10;ALA A  31;LYS A  33;VAL A  64;PHE A  80;PHE A  82;LEU A 133","None","0.66A","3miyA-1h4lA:20.5","3miyA-1h4lA:24.35"],["3MIY_A_B49A1_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"ALA A 428;LYS A 430;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.76A","3miyA-1k2pA:26.8","3miyA-1k2pA:57.41"],["3MIY_A_B49A1_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"ALA A 428;VAL A 458;MET A 477;GLY A 480;LEU A 528;SER A 538;ASP A 539","None","0.83A","3miyA-1k2pA:26.8","3miyA-1k2pA:57.41"],["3MIY_A_B49A1_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 220;LYS A 222;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.81A","3miyA-1k9aA:32.6","3miyA-1k9aA:26.81"],["3MIY_A_B49A1_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 220;LYS A 222;VAL A 249;MET A 269;GLY A 272;LEU A 321","None","0.70A","3miyA-1k9aA:32.6","3miyA-1k9aA:26.81"],["3MIY_A_B49A1_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 220;VAL A 249;MET A 269;GLY A 272;LEU A 321;SER A 331","None","0.77A","3miyA-1k9aA:32.6","3miyA-1k9aA:26.81"],["3MIY_A_B49A1_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"ALA A 606;VAL A 638;PHE A 654;MET A 657;GLY A 660;LEU A 731","None","0.72A","3miyA-1lufA:32.5","3miyA-1lufA:32.85"],["3MIY_A_B49A1_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 288;VAL A 318;PHE A 336;MET A 337;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 ( 4.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","3miyA-1opkA:30.8","3miyA-1opkA:26.01"],["3MIY_A_B49A1_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"ALA A  99;VAL A 131;MET A 150;GLY A 153;LEU A 201;ASP A 212","ATP A 535 (-3.6A);5EA A1001 (-4.5A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.72A","3miyA-1s9iA:10.2","3miyA-1s9iA:26.41"],["3MIY_A_B49A1_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",8,"ALA A 389;VAL A 419;PHE A 435;MET A 438;GLY A 441;LEU A 489;SER A 499;ASP A 500","None","0.80A","3miyA-1snxA:27.7","3miyA-1snxA:98.86"],["3MIY_A_B49A1_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"ILE A 369;ALA A 389;LYS A 391;PHE A 437;MET A 438;GLY A 441;LEU A 489","None","0.85A","3miyA-1snxA:27.7","3miyA-1snxA:98.86"],["3MIY_A_B49A1_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",9,"ILE A 369;ALA A 389;VAL A 419;PHE A 435;PHE A 437;MET A 438;GLY A 441;LEU A 489;SER A 499","None","0.73A","3miyA-1snxA:27.7","3miyA-1snxA:98.86"],["3MIY_A_B49A1_1","1ua2","Homo sapiens","CELL DIVISION PROTEIN KINASE 7","PF00069(Pkinase)",6,"ALA A  39;LYS A  41;PHE A  91;PHE A  93;MET A  94;LEU A 144","ATP A 381 (-3.6A);ATP A 381 (-2.9A);None;ATP A 381 (-4.1A);None;None","0.63A","3miyA-1ua2A:23.3","3miyA-1ua2A:25.43"],["3MIY_A_B49A1_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",6,"ILE A  10;ALA A  30;VAL A  63;PHE A  79;LEU A 132;ASP A 143","None","0.61A","3miyA-1v0bA:23.3","3miyA-1v0bA:25.58"],["3MIY_A_B49A1_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 293;VAL A 323;PHE A 340;MET A 341;GLY A 344;LEU A 393;ASP A 404","QUE A   1 (-3.5A);None;QUE A   1 (-4.2A);None;QUE A   1 (-3.0A);QUE A   1 (-4.4A);None","0.55A","3miyA-2hckA:31.4","3miyA-2hckA:32.31"],["3MIY_A_B49A1_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"ILE A 635;ALA A 659;LYS A 661;PHE A 709;MET A 710;GLY A 713;LEU A 761;SER A 771","ADP A 400 (-4.9A);ADP A 400 (-3.2A);ADP A 400 (-2.7A);None;None;ADP A 400 ( 4.2A);ADP A 400 ( 4.7A);ADP A 400 ( 4.8A)","0.68A","3miyA-2henA:31.1","3miyA-2henA:37.76"],["3MIY_A_B49A1_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"ALA A 271;LYS A 273;VAL A 301;PHE A 318;MET A 319;GLY A 322;LEU A 371","1BM A 499 (-3.6A);1BM A 499 (-3.8A);None;1BM A 499 (-4.1A);None;1BM A 499 (-3.5A);1BM A 499 (-4.4A)","0.58A","3miyA-2hk5A:26.0","3miyA-2hk5A:39.85"],["3MIY_A_B49A1_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"ALA A 269;LYS A 271;VAL A 299;PHE A 317;MET A 318;GLY A 321;LEU A 370","GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-4.6A);GIN A 600 (-4.3A);None;None;GIN A 600 (-4.7A)","0.57A","3miyA-2hz0A:31.8","3miyA-2hz0A:42.18"],["3MIY_A_B49A1_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",7,"ILE A  10;ALA A  31;LYS A  33;VAL A  64;PHE A  80;PHE A  82;LEU A 134","None","0.78A","3miyA-2jgzA:19.6","3miyA-2jgzA:29.15"],["3MIY_A_B49A1_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ILE A 428;ALA A 452;LYS A 454;VAL A 484;GLY A 505;LEU A 553","BII A1687 (-3.8A);BII A1687 (-3.5A);BII A1687 (-2.9A);None;BII A1687 (-3.6A);BII A1687 (-4.2A)","0.79A","3miyA-2jkmA:33.1","3miyA-2jkmA:37.05"],["3MIY_A_B49A1_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",6,"ALA A 271;LYS A 273;VAL A 301;MET A 319;GLY A 322;LEU A 371","1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);None;1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.75A","3miyA-2og8A:32.2","3miyA-2og8A:42.11"],["3MIY_A_B49A1_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"ALA A 367;LYS A 369;VAL A 399;GLY A 418;LEU A 468;SER A 478;ASP A 479","ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;ANP A 615 ( 4.0A);ANP A 615 (-4.7A); MG A 614 ( 4.1A); MG A 614 ( 3.2A)","1.23A","3miyA-2ozoA:29.4","3miyA-2ozoA:19.21"],["3MIY_A_B49A1_1","2pmi","Saccharomyces cerevisiae","CYCLIN-DEPENDENT PROTEIN KINASE PHO85","PF00069(Pkinase)",7,"ALA A  34;LYS A  36;VAL A  66;PHE A  82;PHE A  84;MET A  85;LEU A 140","AGS A3001 (-3.5A);AGS A3001 (-3.4A);None;None;AGS A3001 ( 4.5A);None;None","0.65A","3miyA-2pmiA:21.8","3miyA-2pmiA:29.32"],["3MIY_A_B49A1_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"ILE B  47;ALA B  67;LYS B  69;VAL B  98;MET B 117;GLY B 120;LEU B 171","None","0.58A","3miyA-2qkwB:24.8","3miyA-2qkwB:30.79"],["3MIY_A_B49A1_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"ILE B  47;LYS B  69;VAL B  98;MET B 117;LEU B 171;ASP B 182","None","0.82A","3miyA-2qkwB:24.8","3miyA-2qkwB:30.79"],["3MIY_A_B49A1_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A 651;LYS A 653;MET A 702;GLY A 705;LEU A 753;SER A 763","PTR A 701 ( 4.7A);None;PTR A 701 ( 3.5A);None;None;None","0.52A","3miyA-2qobA:27.5","3miyA-2qobA:38.00"],["3MIY_A_B49A1_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ILE A 681;ALA A 705;LYS A 707;MET A 756;GLY A 759;LEU A 807;SER A 817","None","0.63A","3miyA-2r2pA:29.6","3miyA-2r2pA:36.86"],["3MIY_A_B49A1_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"ALA A 749;LYS A 751;MET A 799;GLY A 802;LEU A 850;ASP A 861","GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-4.1A)","0.78A","3miyA-2r4bA:27.0","3miyA-2r4bA:33.54"],["3MIY_A_B49A1_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"ALA A 749;VAL A 781;MET A 799;GLY A 802;LEU A 850;ASP A 861","GW7 A   1 (-3.3A);GW7 A   1 ( 4.7A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-4.1A)","0.69A","3miyA-2r4bA:27.0","3miyA-2r4bA:33.54"],["3MIY_A_B49A1_1","2wtk","Homo sapiens","STE20-RELATED KINASE ADAPTER PROTEIN ALPHA","PF00069(Pkinase)",7,"ILE B  75;VAL B 131;PHE B 149;MET B 150;GLY B 153;LEU B 202;SER B 212","ANP B 432 (-4.4A);None;ANP B 432 ( 4.9A);None;ANP B 432 ( 4.2A);ANP B 432 ( 4.7A);None","0.89A","3miyA-2wtkB:24.4","3miyA-2wtkB:25.07"],["3MIY_A_B49A1_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"ILE A 627;ALA A 651;MET A 702;GLY A 705;LEU A 753;SER A 763","None;Q9G A1898 (-3.2A);None;Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A);Q9G A1898 (-3.2A)","0.33A","3miyA-2xyuA:31.1","3miyA-2xyuA:39.58"],["3MIY_A_B49A1_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",7,"ILE A  30;ALA A  51;MET A 110;GLY A 113;LEU A 160;SER A 170;ASP A 171","B49 A1294 (-3.9A);B49 A1294 (-3.2A);None;B49 A1294 (-3.6A);B49 A1294 (-4.4A);B49 A1294 ( 4.9A);B49 A1294 (-4.2A)","0.90A","3miyA-2y7jA:24.0","3miyA-2y7jA:22.28"],["3MIY_A_B49A1_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",6,"ILE A  30;ALA A  51;PHE A 107;MET A 110;GLY A 113;LEU A 160","B49 A1294 (-3.9A);B49 A1294 (-3.2A);B49 A1294 (-4.0A);None;B49 A1294 (-3.6A);B49 A1294 (-4.4A)","0.73A","3miyA-2y7jA:24.0","3miyA-2y7jA:22.28"],["3MIY_A_B49A1_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"ALA A 273;LYS A 275;VAL A 303;PHE A 321;MET A 322;GLY A 325;LEU A 374","None","0.57A","3miyA-2zv7A:32.9","3miyA-2zv7A:41.52"],["3MIY_A_B49A1_1","3c0i","Homo sapiens","PERIPHERAL PLASMA MEMBRANE PROTEIN CASK","PF00069(Pkinase)",6,"ILE A  18;ALA A  39;LYS A  41;PHE A  91;PHE A  93;MET A  94","3AM A 338 (-4.5A);3AM A 338 (-3.3A);3AM A 338 (-2.9A);3AM A 338 (-3.6A);3AM A 338 ( 4.6A);None","0.81A","3miyA-3c0iA:24.3","3miyA-3c0iA:26.76"],["3MIY_A_B49A1_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ALA A 220;LYS A 222;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.81A","3miyA-3d7uA:27.4","3miyA-3d7uA:43.12"],["3MIY_A_B49A1_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ALA A 220;LYS A 222;VAL A 249;MET A 269;GLY A 272;LEU A 321","None","0.70A","3miyA-3d7uA:27.4","3miyA-3d7uA:43.12"],["3MIY_A_B49A1_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ALA A 220;VAL A 249;MET A 269;GLY A 272;LEU A 321;SER A 331","None","0.77A","3miyA-3d7uA:27.4","3miyA-3d7uA:43.12"],["3MIY_A_B49A1_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",8,"ILE A 639;ALA A 663;VAL A 695;PHE A 713;MET A 714;GLY A 717;LEU A 765;SER A 775","IHZ A1001 ( 4.8A);IHZ A1001 (-3.3A);IHZ A1001 ( 4.9A);None;None;IHZ A1001 ( 3.9A);IHZ A1001 (-4.6A);IHZ A1001 (-3.7A)","0.80A","3miyA-3dkoA:33.0","3miyA-3dkoA:37.22"],["3MIY_A_B49A1_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ALA A 665;MET A 716;GLY A 719;LEU A 767;SER A 777;ASP A 778","None;None;GOL A 403 (-3.4A);None;None;None","0.77A","3miyA-3kulA:33.9","3miyA-3kulA:37.54"],["3MIY_A_B49A1_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",7,"ILE A  25;ALA A  46;LYS A  48;VAL A  79;PHE A 103;PHE A 105;LEU A 156","None","0.87A","3miyA-3mi9A:23.3","3miyA-3mi9A:26.24"],["3MIY_A_B49A1_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",7,"ALA A  49;LYS A  51;VAL A  82;PHE A  98;PHE A 100;MET A 101;LEU A 151","ADP A 314 (-3.5A);ADP A 314 (-2.8A);None;None;ADP A 314 ( 4.3A);None;ADP A 314 (-4.6A)","0.55A","3miyA-3nizA:24.8","3miyA-3nizA:25.99"],["3MIY_A_B49A1_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A 570;VAL A 601;PHE A 617;MET A 620;GLY A 623;LEU A 686","0F4 A 902 (-3.2A);None;0F4 A 902 (-3.4A);None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.59A","3miyA-3v5qA:31.9","3miyA-3v5qA:36.36"],["3MIY_A_B49A1_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"ALA A  96;LYS A  98;VAL A 128;MET A 147;GLY A 150;LEU A 198;ASP A 209","ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.75A","3miyA-3wigA:24.2","3miyA-3wigA:26.33"],["3MIY_A_B49A1_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 866;VAL A 899;PHE A 918;GLY A 922;LEU A1035;ASP A1046","LEV A1201 (-3.5A);None;LEV A1201 (-4.7A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.4A)","0.65A","3miyA-3wzdA:31.4","3miyA-3wzdA:33.66"],["3MIY_A_B49A1_1","3zdu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 3","PF00069(Pkinase)",6,"ALA A  31;LYS A  33;VAL A  63;PHE A  79;PHE A  81;LEU A 132","38R A 350 (-3.4A);38R A 350 (-2.9A);38R A 350 ( 4.9A);38R A 350 (-4.1A);38R A 350 (-4.2A);38R A 350 (-4.3A)","0.64A","3miyA-3zduA:24.2","3miyA-3zduA:25.45"],["3MIY_A_B49A1_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"ILE A 625;ALA A 649;LYS A 651;PHE A 699;MET A 700;GLY A 703;LEU A 751;SER A 761;ASP A 762","None","0.59A","3miyA-3zfxA:34.8","3miyA-3zfxA:38.46"],["3MIY_A_B49A1_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 866;LYS A 868;VAL A 899;PHE A 918;GLY A 922;LEU A1035","B49 A2000 (-3.5A);B49 A2000 (-3.0A);B49 A2000 ( 4.6A);B49 A2000 (-4.4A);B49 A2000 ( 3.7A);B49 A2000 (-4.5A)","0.79A","3miyA-4agdA:30.2","3miyA-4agdA:30.40"],["3MIY_A_B49A1_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A 586;VAL A 617;PHE A 633;MET A 636;GLY A 639;LEU A 699","LTI A1839 (-3.3A);None;LTI A1839 (-3.5A);None;LTI A1839 (-3.4A);LTI A1839 (-4.2A)","0.61A","3miyA-4at3A:31.6","3miyA-4at3A:38.87"],["3MIY_A_B49A1_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"ILE A  97;ALA A 121;LYS A 123;PHE A 171;MET A 172;GLY A 175;LEU A 223","30K A1365 (-4.5A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-4.4A);None;30K A1365 (-3.5A);30K A1365 (-4.5A)","0.58A","3miyA-4aw5A:30.6","3miyA-4aw5A:39.79"],["3MIY_A_B49A1_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",8,"ILE A  97;ALA A 121;PHE A 171;MET A 172;GLY A 175;LEU A 223;SER A 233;ASP A 234","30K A1365 (-4.5A);30K A1365 (-3.2A);30K A1365 (-4.4A);None;30K A1365 (-3.5A);30K A1365 (-4.5A);30K A1365 ( 3.7A);30K A1365 (-3.3A)","0.83A","3miyA-4aw5A:30.6","3miyA-4aw5A:39.79"],["3MIY_A_B49A1_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"ALA A  63;VAL A  94;PHE A 112;GLY A 116;LEU A 164;ASP A 175","XZN A1317 (-3.5A);XZN A1317 (-4.4A);XZN A1317 (-4.5A);XZN A1317 ( 3.7A);XZN A1317 (-4.7A);XZN A1317 (-3.2A)","0.59A","3miyA-4bc6A:22.2","3miyA-4bc6A:28.19"],["3MIY_A_B49A1_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"ILE A 567;ALA A 588;LYS A 590;GLY A 642;LEU A 690;SER A 700;ASP A 701","GUI A 901 (-4.0A);GUI A 901 (-3.4A);GUI A 901 (-2.8A);GUI A 901 (-3.5A);GUI A 901 (-4.3A);GUI A 901 (-3.1A);GUI A 901 ( 4.1A)","0.75A","3miyA-4e93A:35.0","3miyA-4e93A:34.35"],["3MIY_A_B49A1_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"ILE A 567;ALA A 588;LYS A 590;VAL A 620;GLY A 642;LEU A 690;SER A 700","GUI A 901 (-4.0A);GUI A 901 (-3.4A);GUI A 901 (-2.8A);None;GUI A 901 (-3.5A);GUI A 901 (-4.3A);GUI A 901 (-3.1A)","0.64A","3miyA-4e93A:35.0","3miyA-4e93A:34.35"],["3MIY_A_B49A1_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A 541;VAL A 572;PHE A 588;MET A 591;GLY A 594;LEU A 656","None","0.50A","3miyA-4f0iA:25.2","3miyA-4f0iA:38.18"],["3MIY_A_B49A1_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"ALA A 400;LYS A 402;GLY A 454;LEU A 501;SER A 511;ASP A 512","0SB A 701 (-3.3A);0SB A 701 ( 4.8A);0SB A 701 (-3.5A);0SB A 701 (-4.4A);0SB A 701 (-3.2A);0SB A 701 (-3.9A)","0.81A","3miyA-4f4pA:32.1","3miyA-4f4pA:38.49"],["3MIY_A_B49A1_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501;SER A 511","0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-4.4A);0SB A 701 (-3.2A)","0.78A","3miyA-4f4pA:32.1","3miyA-4f4pA:38.49"],["3MIY_A_B49A1_1","4fie","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF00786(PBD)",7,"ILE A 327;ALA A 348;LYS A 350;VAL A 379;PHE A 397;LEU A 447;SER A 457","None;ANP A1001 (-3.6A);ANP A1001 (-3.0A);None;ANP A1001 ( 4.6A);ANP A1001 (-4.7A);ANP A1001 ( 4.4A)","0.80A","3miyA-4fieA:23.1","3miyA-4fieA:24.10"],["3MIY_A_B49A1_1","4fie","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF00786(PBD)",7,"ILE A 327;LYS A 350;VAL A 379;PHE A 397;GLY A 401;LEU A 447;SER A 457","None;ANP A1001 (-3.0A);None;ANP A1001 ( 4.6A);None;ANP A1001 (-4.7A);ANP A1001 ( 4.4A)","0.79A","3miyA-4fieA:23.1","3miyA-4fieA:24.10"],["3MIY_A_B49A1_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501;SER A 511;ASP A 512","ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 (-4.8A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A); MG A 702 ( 4.2A); MG A 702 ( 3.1A)","1.00A","3miyA-4fl3A:31.3","3miyA-4fl3A:19.09"],["3MIY_A_B49A1_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A1148;LYS A1150;VAL A1180;MET A1199;GLY A1202;LEU A1256","0UV A1501 (-3.4A);0UV A1501 (-3.7A);0UV A1501 ( 4.9A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A)","0.61A","3miyA-4fodA:31.5","3miyA-4fodA:36.25"],["3MIY_A_B49A1_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 293;LYS A 295;VAL A 323;MET A 341;GLY A 344;LEU A 393;ASP A 404","0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A);0J9 A 601 (-3.1A)","0.71A","3miyA-4k11A:31.6","3miyA-4k11A:28.27"],["3MIY_A_B49A1_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",8,"ILE A 413;ALA A 434;LYS A 436;VAL A 465;PHE A 483;GLY A 487;LEU A 533;SER A 543","B49 A 701 (-4.2A);B49 A 701 (-3.2A);None;None;B49 A 701 (-4.3A);B49 A 701 ( 3.7A);B49 A 701 (-4.5A);B49 A 701 (-3.0A)","0.65A","3miyA-4ks8A:24.9","3miyA-4ks8A:28.19"],["3MIY_A_B49A1_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",8,"ILE A 413;ALA A 434;VAL A 465;PHE A 483;GLY A 487;LEU A 533;SER A 543;ASP A 544","B49 A 701 (-4.2A);B49 A 701 (-3.2A);None;B49 A 701 (-4.3A);B49 A 701 ( 3.7A);B49 A 701 (-4.5A);B49 A 701 (-3.0A);B49 A 701 (-4.6A)","0.73A","3miyA-4ks8A:24.9","3miyA-4ks8A:28.19"],["3MIY_A_B49A1_1","4l01","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","PF07714(Pkinase_Tyr)",6,"LYS A 622;VAL A 651;PHE A 669;GLY A 673;LEU A 721;SER A 738","None","0.75A","3miyA-4l01A:28.9","3miyA-4l01A:28.62"],["3MIY_A_B49A1_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",7,"ALA A 293;LYS A 295;VAL A 323;MET A 341;GLY A 344;LEU A 393;ASP A 404","VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.8A);None;VGG A 601 ( 3.2A);VGG A 601 (-4.5A);VGG A 601 ( 4.7A)","0.75A","3miyA-4lggA:31.9","3miyA-4lggA:40.94"],["3MIY_A_B49A1_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",7,"ALA A 218;LYS A 220;VAL A 255;MET A 274;LEU A 324;SER A 334;ASP A 335","29X A 702 (-3.1A);29X A 702 (-3.6A);29X A 702 (-4.8A);None;29X A 702 (-4.6A);29X A 702 (-3.4A);29X A 702 (-4.4A)","0.93A","3miyA-4mk0A:15.9","3miyA-4mk0A:17.97"],["3MIY_A_B49A1_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",7,"LYS A 220;VAL A 255;MET A 274;GLY A 277;LEU A 324;SER A 334;ASP A 335","29X A 702 (-3.6A);29X A 702 (-4.8A);None;None;29X A 702 (-4.6A);29X A 702 (-3.4A);29X A 702 (-4.4A)","0.89A","3miyA-4mk0A:15.9","3miyA-4mk0A:17.97"],["3MIY_A_B49A1_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ILE A 619;ALA A 644;MET A 695;GLY A 698;LEU A 746;SER A 756","None","0.69A","3miyA-4p2kA:34.0","3miyA-4p2kA:38.41"],["3MIY_A_B49A1_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"ALA A  35;LYS A  37;VAL A  65;MET A  84;GLY A  87;LEU A 136","ACP A1264 (-2.9A);None;None;None;ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.61A","3miyA-4ueuA:33.1","3miyA-4ueuA:48.36"],["3MIY_A_B49A1_1","4xbr","Homo sapiens","PROTEIN FAM212A,SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF15342(FAM212)",8,"ILE A 327;ALA A 348;LYS A 350;VAL A 379;PHE A 397;LEU A 447;SER A 457;ASP A 458","None;ATP A 601 ( 3.7A);ATP A 601 (-2.8A);None;ATP A 601 (-4.6A);None;ATP A 601 ( 4.6A);ATP A 601 ( 2.5A)","0.84A","3miyA-4xbrA:19.4","3miyA-4xbrA:24.22"],["3MIY_A_B49A1_1","4xbr","Homo sapiens","PROTEIN FAM212A,SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF15342(FAM212)",7,"LYS A 350;VAL A 379;PHE A 397;GLY A 401;LEU A 447;SER A 457;ASP A 458","ATP A 601 (-2.8A);None;ATP A 601 (-4.6A);None;None;ATP A 601 ( 4.6A);ATP A 601 ( 2.5A)","0.85A","3miyA-4xbrA:19.4","3miyA-4xbrA:24.22"],["3MIY_A_B49A1_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",7,"ALA B 288;LYS B 290;VAL B 318;PHE B 336;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.79A","3miyA-4xeyB:26.2","3miyA-4xeyB:30.47"],["3MIY_A_B49A1_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 428;VAL A 458;MET A 477;GLY A 480;LEU A 528;SER A 538;ASP A 539","None","0.67A","3miyA-4xi2A:29.4","3miyA-4xi2A:42.94"],["3MIY_A_B49A1_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",8,"ALA A 428;LYS A 430;VAL A 458;MET A 477;GLY A 480;LEU A 528;SER A 538;ASP A 539","746 A 702 (-2.4A);746 A 702 (-3.7A);None;None;746 A 702 (-3.6A);746 A 702 (-4.4A);746 A 702 ( 3.8A);746 A 702 (-3.7A)","0.65A","3miyA-4y93A:33.1","3miyA-4y93A:35.57"],["3MIY_A_B49A1_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"ILE A  10;ALA A  31;LYS A  33;VAL A  64;PHE A  80;LEU A 135;ASP A 146","None","0.74A","3miyA-4yc6A:23.5","3miyA-4yc6A:30.69"],["3MIY_A_B49A1_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"ILE A  10;ALA A  31;VAL A  64;PHE A  80;PHE A  82;LEU A 135;ASP A 146","None","0.66A","3miyA-4yc6A:23.5","3miyA-4yc6A:30.69"],["3MIY_A_B49A1_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",6,"ALA A 214;LYS A 216;VAL A 248;MET A 267;LEU A 319;SER A 329","AN2 A 601 (-3.6A);AN2 A 601 ( 3.9A);None;None;None;AN2 A 601 ( 4.5A)","0.80A","3miyA-4yhjA:20.3","3miyA-4yhjA:18.92"],["3MIY_A_B49A1_1","5ci6","Arabidopsis thaliana","MITOGEN-ACTIVATED PROTEIN KINASE 6","PF00069(Pkinase)",6,"ILE A  69;ALA A  90;LYS A  92;VAL A 123;MET A 147;LEU A 196","None","0.54A","3miyA-5ci6A:22.0","3miyA-5ci6A:23.87"],["3MIY_A_B49A1_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",6,"ILE A 396;ALA A 417;LYS A 419;VAL A 449;GLY A 471;LEU A 518","GUI A 701 (-4.1A);GUI A 701 ( 3.9A);GUI A 701 (-3.1A);None;GUI A 701 (-3.6A);GUI A 701 (-4.4A)","0.80A","3miyA-5jznA:23.3","3miyA-5jznA:25.00"],["3MIY_A_B49A1_1","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",6,"ILE A 639;ALA A 663;PHE A 713;MET A 714;LEU A 765;SER A 775","6P6 A1001 (-4.0A);6P6 A1001 (-3.3A);6P6 A1001 ( 4.5A);None;6P6 A1001 (-4.5A);6P6 A1001 ( 3.7A)","0.45A","3miyA-5l6oA:32.6","3miyA-5l6oA:38.26"],["3MIY_A_B49A1_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",9,"ILE A 889;ALA A 909;LYS A 911;VAL A 940;PHE A 958;MET A 959;GLY A 962;LEU A1016;ASP A1027","None;ATP A1200 (-3.5A);ATP A1200 (-3.8A);None;ATP A1200 ( 4.0A);None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A);ATP A1200 (-4.1A)","0.65A","3miyA-5lpyA:24.6","3miyA-5lpyA:30.67"],["3MIY_A_B49A1_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",9,"ILE A 889;ALA A 909;LYS A 911;VAL A 940;PHE A 958;MET A 959;GLY A 962;LEU A1016;SER A1026","None;ATP A1200 (-3.5A);ATP A1200 (-3.8A);None;ATP A1200 ( 4.0A);None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A);ATP A1200 ( 4.7A)","0.49A","3miyA-5lpyA:24.6","3miyA-5lpyA:30.67"],["3MIY_A_B49A1_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",9,"ILE A 889;ALA A 909;LYS A 911;VAL A 940;PHE A 958;MET A 959;GLY A 962;LEU A1016;ASP A1027","ADP A1200 (-4.7A);ADP A1200 (-3.5A);ADP A1200 ( 4.3A);None;ADP A1200 (-4.1A);None;ADP A1200 ( 4.0A);ADP A1200 (-4.7A);ADP A1200 (-3.4A)","0.66A","3miyA-5lpzA:24.5","3miyA-5lpzA:28.57"],["3MIY_A_B49A1_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",8,"ILE A 889;ALA A 909;VAL A 940;PHE A 958;MET A 959;GLY A 962;LEU A1016;SER A1026","ADP A1200 (-4.7A);ADP A1200 (-3.5A);None;ADP A1200 (-4.1A);None;ADP A1200 ( 4.0A);ADP A1200 (-4.7A);ADP A1200 ( 4.6A)","0.64A","3miyA-5lpzA:24.5","3miyA-5lpzA:28.57"],["3MIY_A_B49A1_1","5tos","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE BIK1","no annotation",7,"ALA A 103;VAL A 134;PHE A 152;MET A 153;GLY A 156;LEU A 209;SER A 219","None","0.98A","3miyA-5tosA:22.9","3miyA-5tosA:14.98"],["3MIY_A_B49A1_1","5u6b","Homo sapiens","TYROSINE-PROTEIN KINASE RECEPTOR UFO","PF07714(Pkinase_Tyr)",6,"ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.81A","3miyA-5u6bA:32.2","3miyA-5u6bA:36.93"],["3MIY_A_B49A1_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"ILE A  98;ALA A 119;LYS A 121;VAL A 153;MET A 172;LEU A 221","None","0.78A","3miyA-5u7qA:19.6","3miyA-5u7qA:23.66"],["3MIY_A_B49A1_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",7,"ALA A 218;LYS A 220;VAL A 255;MET A 274;LEU A 324;SER A 334;ASP A 335","QRW A 601 (-3.4A);QRW A 601 (-3.0A);None;MES A 604 (-3.9A);None;QRW A 601 ( 3.7A);QRW A 601 (-3.7A)","0.95A","3miyA-5uuuA:22.1","3miyA-5uuuA:18.54"],["3MIY_A_B49A1_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",7,"LYS A 220;VAL A 255;MET A 274;GLY A 277;LEU A 324;SER A 334;ASP A 335","QRW A 601 (-3.0A);None;MES A 604 (-3.9A);None;None;QRW A 601 ( 3.7A);QRW A 601 (-3.7A)","0.96A","3miyA-5uuuA:22.1","3miyA-5uuuA:18.54"],["3MIY_A_B49A1_1","5vef","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","no annotation",9,"ILE A 327;ALA A 348;LYS A 350;VAL A 379;PHE A 397;GLY A 401;LEU A 447;SER A 457;ASP A 458","M77 A 601 ( 4.8A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 (-3.2A);M77 A 601 ( 3.5A)","0.87A","3miyA-5vefA:24.1","3miyA-5vefA:27.07"],["3MIY_A_B49A1_1","5win","-","-","no annotation",6,"LYS A 581;VAL A 610;PHE A 628;GLY A 632;LEU A 680;SER A 698","SKE A 901 ( 4.7A);SKE A 901 ( 4.7A);SKE A 901 (-3.6A);SKE A 901 (-3.1A);SKE A 901 (-4.1A);SKE A 901 (-3.3A)","0.70A","3miyA-5winA:29.2","3miyA-5winA:undetectable"],["3MIY_A_B49A1_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",7,"ILE A 733;ALA A 754;LYS A 756;VAL A 787;PHE A 813;MET A 816;LEU A 866","CJM A1102 (-3.4A);CJM A1102 (-3.1A);None;None;CJM A1102 ( 4.4A);None;CJM A1102 (-4.4A)","0.82A","3miyA-6b3eA:23.9","3miyA-6b3eA:16.02"],["3MIY_A_B49A1_1","6bfn","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1","no annotation",8,"ILE A 218;ALA A 237;LYS A 239;VAL A 272;PHE A 290;GLY A 294;LEU A 347;ASP A 358","DL1 A 601 (-4.0A);DL1 A 601 (-3.4A);DL1 A 601 ( 4.1A);DL1 A 601 ( 4.8A);DL1 A 601 (-4.3A);DL1 A 601 (-3.5A);DL1 A 601 (-3.9A);DL1 A 601 (-3.1A)","0.61A","3miyA-6bfnA:25.0","3miyA-6bfnA:15.81"],["3MIY_A_B49A1_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",7,"ILE A 171;ALA A 192;LYS A 194;VAL A 249;PHE A 267;GLY A 273;LEU A 319","BI9 A 501 (-4.0A);BI9 A 501 (-3.3A);NH4 A 506 ( 4.4A);None;BI9 A 501 ( 4.2A);BI9 A 501 (-3.3A);BI9 A 501 (-4.7A)","0.59A","3miyA-6bqlA:23.0","3miyA-6bqlA:14.94"],["3MIY_A_B49A1_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",6,"ALA A 906;LYS A 908;VAL A 938;PHE A 958;GLY A 962;LEU A1010","ADP A1201 (-3.4A);ADP A1201 (-2.8A);None;None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.62A","3miyA-6c7yA:29.7","3miyA-6c7yA:16.00"],["3MIY_A_B49A1_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",7,"ILE A 134;ALA A 155;LYS A 157;VAL A 212;PHE A 230;GLY A 236;LEU A 282","H1N A 501 (-4.3A);H1N A 501 (-3.4A);H1N A 501 (-2.8A);H1N A 501 (-4.9A);H1N A 501 (-3.7A);H1N A 501 (-3.6A);H1N A 501 (-4.8A)","0.58A","3miyA-6ccfA:23.4","3miyA-6ccfA:13.74"],["3MIY_A_B49A1_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"ILE A 171;ALA A 192;VAL A 249;PHE A 267;GLY A 273;LEU A 319","F6J A 501 (-4.3A);F6J A 501 (-3.4A);None;F6J A 501 (-3.7A);F6J A 501 ( 3.7A);F6J A 501 (-4.5A)","0.77A","3miyA-6cmjA:22.9","3miyA-6cmjA:16.59"],["3MIY_A_B49A1_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",6,"ALA A 211;VAL A 246;MET A 265;GLY A 268;LEU A 318;SER A 328","CJT A 502 (-3.4A);None;CJT A 502 (-4.9A);CJT A 502 ( 4.3A);CJT A 502 (-4.7A);CJT A 502 ( 4.3A)","0.73A","3miyA-6f3dA:25.4","3miyA-6f3dA:13.17"]]